The daily AI confidence map for psychedelic FDA approval — psilocybin, MDMA, and ketamine — set side by side with the prediction markets.
Last updated: 2026-06-25 · View all Oracle predictions →
What are the real odds the FDA approves a psychedelic in 2026? Prediction markets answer with one number — Polymarket trades near 36% on "FDA approves a psychedelic for medical use in 2026," and Kalshi runs a similar contract. That single figure is useful, but it collapses a complex, multi-drug regulatory race into one coin flip moved by traders.
The OOTWOracle answers differently. Each morning it runs up to ~460 signals through an 8-agent AI swarm and publishes a confidence-scored probability for every pathway separately — psilocybin, MDMA, ketamine, DEA rescheduling, and federal legislation — each with a resolution date and a public accuracy record. This page is that live odds map, updated daily, set directly against the prediction markets.
A single prediction-market number vs. the Oracle's daily, per-pathway confidence. Oracle figures refresh every morning; the values below reflect late-June 2026 signal.
| Question | Prediction market | OOTWOracle (daily) |
|---|---|---|
| Any psychedelic FDA-approved in 2026 | ~36% (Polymarket) | Possible, not base case |
| Near-term action favors ketamine-class over MDMA/psilocybin | — (no market) | 74% confidence |
| No federal psilocybin rescheduling this Congress | — (no market) | 72% confidence |
| MDMA approval decision slips past 2027 | — (no market) | ~72% confidence |
Prediction markets price one binary question. The Oracle scores the whole board — which is why it can tell you not just whether a psychedelic is approved, but which one, when, and under what conditions.
A prediction market is a powerful tool, but it has structural blind spots for a question like this. It resolves one yes/no contract; psychedelic approval is really a dozen interlocking questions (which drug, which indication, what label restrictions, FDA vs. DEA timing). Markets can be thin and slow to move on niche regulatory events, and they tell you a price, not a reason.
The Oracle is built for exactly this shape of problem. Eight specialized agents — an FDA reviewer, a DEA officer, a legislator, a neuroscientist, a veteran advocate, and others — debate each day's signals and converge on confidence scores with explicit reasoning. Every prediction is falsifiable, carries a resolution date, and feeds a public accuracy record. You get a probability and the regulatory logic behind it, refreshed daily.
Compass Pathways COMP360 (psilocybin). Two successful Phase 3 trials in treatment-resistant depression and an FDA Priority Review Voucher — which can compress review to 1–2 months — make a late-2026/early-2027 decision plausible if the NDA lands in Q4 2026. This is the single biggest upside catalyst for the "any approval in 2026" odds.
The April 2026 executive order & priority vouchers. The White House order on accelerating treatments for serious mental illness, followed by FDA National Priority Vouchers to Compass, Usona, and Transcend, structurally shortened timelines — and pointedly favored psilocybin and methylone, not MDMA.
MDMA's unblinding problem. After the 2024 Complete Response Letter to Lykos and a request for another Phase 3 trial, MDMA remains the laggard on the science even as it leads on veteran political momentum. This is the main reason the Oracle ranks ketamine-class and psilocybin ahead of MDMA for first approval.
FDA vs. DEA timing. Even a "yes" from the FDA starts a separate, slower DEA rescheduling clock. Any honest odds map has to price the gap between approval and actual pharmacy access — which is why the Oracle scores them as separate questions.
What are the odds the FDA approves a psychedelic in 2026? Polymarket trades near 36% on the single "any psychedelic in 2026" question. The Oracle's per-pathway read: possible but not the base case, with ketamine-class agents (~74%) ahead of MDMA and psilocybin for first approval.
How are Oracle odds different from Polymarket or Kalshi? Markets give one number on one binary, moved by traders. The Oracle gives daily, confidence-scored odds across the whole field — each with a resolution date and a public accuracy record.
Which psychedelic is most likely to be approved first? On current signal, a ketamine-class agent with clean blinding or Compass's psilocybin (COMP360) — not MDMA, which still needs another trial.
What are the odds the FDA approves MDMA in 2026? Low. The Oracle expects any MDMA decision to slip past 2027 due to unresolved trial-blinding concerns.
How often are these odds updated? Every day — the full signal swarm re-runs each morning and the confidence scores on this page refresh with it.
The OOTWOracle publishes a fresh, confidence-scored read on psychedelic FDA approval every day — free, falsifiable, and tracked for accuracy.
From the science of psilocybin to your personal journey — the full OOTW ecosystem supports every layer of this work.